Literature DB >> 19890630

Key role of nuclear medicine in bringing imaging biomarkers into clinical practice.

Ignasi Carrió.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19890630     DOI： 10.1007/s00259-009-1318-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  A decade of combined imaging: from a PET attached to a CT to a PET inside an MR.

Authors:  Thomas Beyer; Bernd Pichler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

2.  Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI.

Authors:  Pieter Jelle Visser; David S Knopman
Journal:  Neurology       Date:  2009-07-29       Impact factor: 9.910

3.  Of impact, metrics and ethics.

Authors:  Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06       Impact factor: 9.236

4.  Practice-based evidence of the beneficial impact of positron emission tomography in clinical oncology.

Authors:  Steven M Larson
Journal:  J Clin Oncol       Date:  2008-03-24       Impact factor: 44.544

5.  Assessing the prognostic value of cardiovascular imaging: a statistical exercise or a guide to clinical value and application?

Authors:  Rory Hachamovitch
Journal:  Circulation       Date:  2009-09-21       Impact factor: 29.690

6.  The future's bright: imaging cell biology in the 21st century.

Authors:  C Rose Hosking; Jennifer Lippincott Schwartz
Journal:  Trends Cell Biol       Date:  2009-10-14       Impact factor: 20.808

7.  The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.

Authors:  G W Goerres; R Stupp; G Barghouth; T F Hany; B Pestalozzi; E Dizendorf; P Schnyder; F Luthi; G K von Schulthess; S Leyvraz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

8.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

9.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

10.  [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.

Authors:  Gabriela Kramer-Marek; Dale O Kiesewetter; Lucia Martiniova; Elaine Jagoda; Sang Bong Lee; Jacek Capala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-22       Impact factor: 9.236
  10 in total
  3 in total

1.  Imaging of neuroinflammation.

Authors:  Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12       Impact factor: 9.236

2.  Key role of nuclear medicine in seeking biomarkers of Huntington's disease.

Authors:  Ferdinando Squitieri; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

Review 3.  'Image and treat': an individualized approach to urological tumors.

Authors:  Kirsten Bouchelouche; Jacek Capala
Journal:  Curr Opin Oncol       Date:  2010-05       Impact factor: 3.645
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.